NCT02711852 2023-09-11
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
SecuraBio
Phase 2 Completed
Clinical Trials
4 trialsNCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT02605694 2021-03-17
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
SecuraBio
Phase 2 Withdrawn
NCT04707079 2021-01-13
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown